

Supplementary Material

Supplementary Table 1. MOOSE checklist

*on the supplementary materials

Item No	Recommendation	Reported on Page No
Reporting of background should include		
1	Problem definition	2
2	Hypothesis statement	3
3	Description of study outcome(s)	3,4
4	Type of exposure or intervention used	3
5	Type of study designs used	3
6	Study population	3
Reporting of search strategy should include		
7	Qualifications of searchers (eg, librarians and investigators)	3,4
8	Search strategy, including time period included in the synthesis and key words	3, Table 2*
9	Effort to include all available studies, including contact with authors	3, without contact authors
10	Databases and registries searched	3
11	Search software used, name and version, including special features used (eg, explosion)	3
12	Use of hand searching (eg, reference lists of obtained articles)	NA
13	List of citations located and those excluded, including justification	Figure 1, Table 4*
14	Method of addressing articles published in languages other than English	NA
15	Method of handling abstracts and unpublished studies	NA
16	Description of any contact with authors	NA
Reporting of methods should include		
17	Description of relevance or appropriateness of studies assembled for	3

	assessing the hypothesis to be tested	
18	Rationale for the selection and coding of data (eg, sound clinical principles or convenience)	3,4
19	Documentation of how data were classified and coded (eg, multiple raters, blinding and interrater reliability)	3,4
20	Assessment of confounding (eg, comparability of cases and controls in studies where appropriate)	4-6
21	Assessment of study quality, including blinding of quality assessors, stratification or regression on possible predictors of study results	5
22	Assessment of heterogeneity	4-6
23	Description of statistical methods (eg, complete description of fixed or random effects models, justification of whether the chosen models account for predictors of study results, dose-response models, or cumulative meta-analysis) in sufficient detail to be replicated	4
24	Provision of appropriate tables and graphics	Figure 1-5 Table 1-2 Table 1-4* Figure 1-2*
Reporting of results should include		
25	Table giving descriptive information for each study included	Table 1
26	Results of sensitivity testing (eg, subgroup analysis)	Table 2, Figure 2*
27	Indication of statistical uncertainty of findings	6-8
Reporting of Discussion		
28	Quantitative assessment of bias (eg, publication bias)	Figure 5
29	Justification for exclusion (eg, exclusion of non-English-language citations)	Figure 1, Table 4*
30	Assessment of quality of included studies	Table 3*
Reporting of Conclusions		
31	Consideration of alternative explanations for observed results	6-8
32	Generalization of the conclusions (ie, appropriate for the data presented and within the domain of the literature review)	8
33	Guidelines for future research	8
34	Disclosure of funding source	8-9

From: Brooke BS, Schwartz TA, Pawlik TM. MOOSE Reporting Guidelines for Meta-analyses of Observational Studies. *JAMA Surg.* 2021;156(8):787–788.
doi:10.1001/jamasurg.2021.0522

Supplementary Table 2. Details of search strategy

Database	PubMed.
Search	#1 "Neoplasms"[Mesh]
Terms	#2 cancer*[Text word] OR Tumor*[Text word] OR malignan*[Text word] OR neoplas*[Text word] OR tumour*[Text word] OR carcinoma*[Text word] OR adenocarcinoma*[Text word] OR choriocarcinoma*[Text word] OR lymphoma*[Text word] OR leukemia*[Text word] OR leukaemia*[Text word] OR metastat*[Text word] OR sarcoma*[Text word] OR teratoma*[Text word] OR Epithelioma*[Text word] #3 #1 OR #2 #4 "Antidepressive Agents"[MeSH Terms] OR "Serotonin Uptake Inhibitors"[MeSH Terms] OR "Adrenergic Uptake Inhibitors"[MeSH Terms] OR "Monoamine Oxidase Inhibitors"[MeSH Terms] #5 "anti-depress*"[Text Word] OR "trycyclic*"[Text Word] OR "tca"[Text Word] OR "ssri*"[Text Word] OR "serotonin uptake*"[Text Word] OR "snri*"[Text Word] OR "monoamine oxidase inhibitor*"[Text Word] OR "maoi*"[Text Word] OR "mao inhibitor*"[Text Word] OR "thymoanaleptic*"[Text Word] OR "thymoleptic*"[Text Word] OR "5 hydroxytryptamine*"[Text Word] OR "5 ht*"[Text Word] OR "rima*"[Text Word] #6 "desipramine*"[Text Word] OR "imipramine*"[Text Word] OR "clomipramine*"[Text Word] OR "opipramol*"[Text Word] OR "trimipramine*"[Text Word] OR "lofepramine*"[Text Word] OR "dibenzepin*"[Text Word] OR "amitriptyline*"[Text Word] OR "nortriptyline*"[Text Word] OR "protriptyline*"[Text Word] OR "doxepin*"[Text Word] OR "iprindole*"[Text Word] OR "melitracen*"[Text Word] OR "butriptyline*"[Text Word] OR "dosulepin*"[Text Word] OR "amoxapine*"[Text Word] OR "dimetacrine*"[Text Word] OR "amineptine*"[Text Word] OR "maprotiline*"[Text Word] OR "quinupramine*"[Text Word] OR "zimeldine*"[Text Word] OR "fluoxetine*"[Text Word] OR "citalopram*"[Text Word] OR "paroxetine*"[Text Word] OR "sertraline*"[Text Word] OR "alaproclate*"[Text Word] OR "fluvoxamine*"[Text Word] OR "etoperidone*"[Text Word] OR "escitalopram*"[Text Word] OR "isocarboxazid*"[Text Word] OR "nialamide*"[Text Word] OR "phenelzine*"[Text Word] OR "tranylcypromine*"[Text Word] OR "iproniazide*"[Text Word] OR "iproclozide*"[Text Word] OR "moclobemide*"[Text Word] OR "toloxatone*"[Text Word] OR "oxitriptan*"[Text Word] OR "tryptophan*"[Text Word] OR "mianserin*"[Text Word] OR "nomifensine*"[Text Word] OR "trazodone*"[Text Word] OR "nefazodone*"[Text Word] OR "minaprine*"[Text Word] OR "bifemelane*"[Text Word] OR "viloxazine*"[Text Word] OR "oxaflozane*"[Text Word] OR

	"mirtazapine*[Text Word] OR "bupropion*[Text Word] OR "medifoxamine*[Text Word] OR "tianeptine*[Text Word] OR "pivagabine*[Text Word] OR "venlafaxine*[Text Word] OR "milnacipran*[Text Word] OR "reboxetine*[Text Word] OR "gepirone*[Text Word] OR "duloxetine*[Text Word] OR "agomelatine*[Text Word] OR "desvenlafaxine*[Text Word] OR "vilazodone*[Text Word] OR "hyperici herba*[Text Word] OR "hypericum perforatum*[Text Word] OR "st john* wort*[Text Word] OR "vortioxetine*[Text Word] OR "esketamine*[Text Word] OR "levomilnacipran*[Text Word] OR "Clovoxamine*[Text Word] OR "Clorgyline*[Text Word] OR "Dothiepin*[Text Word] OR "Sulpiride*[Text Word] OR "Rolipram*[Text Word] #7 #4 OR #5 OR #6 #8 "morbidity"[MeSH Terms] OR "incidence"[MeSH Terms] OR "risk"[MeSH Terms] #9 "morbidity*[Text Word] OR "incidence*[Text Word] OR "occurrence*[Text Word] OR "genesis*[Text Word] OR "occur*[Text Word] OR "risk*[Text Word] #10 #8 OR #9 #11 "Case-Control Studies"[MeSH Terms] OR "Cohort Studies"[MeSH Terms] #12 "case*[Text Word] AND ("control*[Text Word] OR "comparison*[Text Word] OR "compeer*[Text Word] OR "referrent*[Text Word] OR "base*[Text Word]) #13 "cohort*[Text Word] OR "longitudinal*[Text Word] OR "prospective*[Text Word] OR "follow-up*[Text Word] OR "retrospective*[Text Word] #14 #11 OR #12 OR #13 #15 #14 AND #10 AND #7 AND #3 #16 "Animals"[Mesh] #17 "Humans"[Mesh] #18 #16 NOT #17 #19 #15 NOT #18
Database	Web of Science
Search	#1 TS=(Antidepressive Agent* or Serotonin Uptake Inhibitor* or Adrenergic Uptake Inhibitors* or Monoamine Oxidase Inhibitor* or anti-depress* or

Terms	antidepress* or tricyclic* or TCA* or serotonin uptake or SSRI* or SNRI* or monoamine oxidase inhibitor* or MAOI* or mao inhibitor* or thymoanaleptic* or thymoleptic* or 5 hydroxytryptamine* or 5-hydroxytryptamine* or 5 ht or 5-ht* or rima* or desipramine* or imipramine* or clomipramine* or opipramol* or trimipramine* or lofepramine* or dibenzepin* or amitriptyline* or nortriptyline* or protriptyline* or doxepin* or iprindole* or melitracen* or butriptyline* or dosulepin* or amoxapine* or dimetacrine* or amineptine* or maprotiline* or quinupramine* or zimeldine* or fluoxetine* or citalopram* or paroxetine* or sertraline* or alaproclate* or fluvoxamine* or etoperidone* or escitalopram* or isocarboxazid* or nialamide* or phenelzine* or tranlycypromine* or iproniazide* or iproclozide* or moclobemide* or toloxatone* or oxitriptan* or tryptophan* or mianserin* or nomifensine* or trazodone* or nefazodone* or minaprine* or bifemelane* or viloxazine* or oxaflozane* or mirtazapine* or bupropion* or medifoxamine* or tianeptine* or pivagabine* or venlafaxine* or milnacipran* or reboxetine* or gepirone* or duloxetine* or agomelatine* or desvenlafaxine* or vilazodone* or hyperici herba* or hypericum perforatum* or st john* wort* or vortioxetine* or esketamine* or levomilnacipran* or Clovoxamine* or Clorgyline* or Dothiepin* or Sulpiride* or Rolipram*) # 2 (TS=(case*)) AND TS=((control* or comparison* or compeer* or referrent* or base*)) # 3 TS=(cohort* or longitudinal* or prospective* or retrospective* or follow-up*) # 4 #2 OR #3 # 5 TS=(morbidity* or incidence* or occurrence* or genesis* or occur* or risk*) # 6 TS=(Neoplasms* or cancer* or tumor* or tumour* or neoplas* or malignan* or carcinoma* or adenocarcinoma* or choriocarcinoma* or lymphoma* or leukemia* or leukaemia* or metastat* or sarcoma* or teratoma* or epithelioma*) #7 #1 AND #4 AND #5 AND #6
Database	Embase
Search Terms	#1 'neoplasm'/exp OR cancer*:ti,ab,kw OR tumor*:ti,ab,kw OR malignan*:ti,ab,kw OR neoplas*:ti,ab,kw OR tumour*:ti,ab,kw OR carcinoma*:ti,ab,kw OR adenocarcinoma*:ti,ab,kw OR choriocarcinoma*:ti,ab,kw OR lymphoma*:ti,ab,kw OR leukemia*:ti,ab,kw OR leukaemia*:ti,ab,kw OR metastat*:ti,ab,kw OR sarcoma*:ti,ab,kw OR teratoma*:ti,ab,kw OR epithelioma*:ti,ab,kw #2 desipramine*:ti,ab,kw OR imipramine*:ti,ab,kw OR clomipramine*:ti,ab,kw OR opipramol*:ti,ab,kw OR trimipramine*:ti,ab,kw OR lofepramine*:ti,ab,kw OR dibenzepin*:ti,ab,kw OR amitriptyline*:ti,ab,kw OR nortriptyline*:ti,ab,kw OR protriptyline*:ti,ab,kw OR doxepin*:ti,ab,kw OR iprindole*:ti,ab,kw OR

melitracen*:ti,ab,kw OR butriptyline*:ti,ab,kw OR dosulepin*:ti,ab,kw OR amoxapine*:ti,ab,kw OR dimetacrine*:ti,ab,kw OR amineptine*:ti,ab,kw OR maprotiline*:ti,ab,kw OR quinupramine*:ti,ab,kw OR zimeldine*:ti,ab,kw OR fluoxetine*:ti,ab,kw OR citalopram*:ti,ab,kw OR paroxetine*:ti,ab,kw OR sertraline*:ti,ab,kw OR alaproclate*:ti,ab,kw OR fluvoxamine*:ti,ab,kw OR etoperidone*:ti,ab,kw OR escitalopram*:ti,ab,kw OR isocarboxazid*:ti,ab,kw OR nialamide*:ti,ab,kw OR phenelzine*:ti,ab,kw OR tranlycypromine*:ti,ab,kw OR iproniazide*:ti,ab,kw OR iproclozide*:ti,ab,kw OR moclobemide*:ti,ab,kw OR toloxatone*:ti,ab,kw OR oxitriptan*:ti,ab,kw OR tryptophan*:ti,ab,kw OR mianserin*:ti,ab,kw OR nomifensine*:ti,ab,kw OR trazodone*:ti,ab,kw OR nefazodone*:ti,ab,kw OR minaprine*:ti,ab,kw OR bifemelane*:ti,ab,kw OR viloxazine*:ti,ab,kw OR oxaflozane*:ti,ab,kw OR mirtazapine*:ti,ab,kw OR bupropion*:ti,ab,kw OR medifoxamine*:ti,ab,kw OR tianeptine*:ti,ab,kw OR pivagabine*:ti,ab,kw OR venlafaxine*:ti,ab,kw OR milnacipran*:ti,ab,kw OR reboxetine*:ti,ab,kw OR gepirone*:ti,ab,kw OR duloxetine*:ti,ab,kw OR agomelatine*:ti,ab,kw OR desvenlafaxine*:ti,ab,kw OR vilazodone*:ti,ab,kw OR 'hyperici herba*:ti,ab,kw OR 'hypericum perforatum*:ti,ab,kw OR 'st john* wort*:ti,ab,kw OR vortioxetine*:ti,ab,kw OR esketamine*:ti,ab,kw OR levomilnacipran*:ti,ab,kw OR clovoxamine*:ti,ab,kw OR clorgyline*:ti,ab,kw OR sulpiride*:ti,ab,kw OR dothiepin*:ti,ab,kw OR rolipram*:ti,ab,kw #3 'morbidity'/exp OR 'incidence'/exp OR 'risk'/exp #4 morbidit*:ti,ab,kw OR incidence*:ti,ab,kw OR occurrence*:ti,ab,kw OR genesis*:ti,ab,kw OR occur*:ti,ab,kw OR risk*:ti,ab,kw #5 #3 OR #4 #6 'case control study'/exp OR 'cohort analysis'/exp #7 control*:ti,ab,kw OR comparison*:ti,ab,kw OR compeer*:ti,ab,kw OR referrent*:ti,ab,kw OR base*:ti,ab,kw #8 cohort*:ti,ab,kw OR longitudinal*:ti,ab,kw OR prospective*:ti,ab,kw OR 'follow up*:ti,ab,kw OR retrospective*:ti,ab,kw #9 case*:ti,ab,kw #10 #7 AND #9 #11 #6 OR #8 OR #10 #12 antidepressent*:ti,ab,kw OR 'anti-depress*:ti,ab,kw OR tricyclic*:ti,ab,kw OR tca*:ti,ab,kw OR ssri*:ti,ab,kw OR 'serotonin uptake*:ti,ab,kw OR snri*:ti,ab,kw OR maoi*:ti,ab,kw OR 'mao inhibitor*:ti,ab,kw OR thymoanaleptic*:ti,ab,kw OR thymoleptic*:ti,ab,kw OR '5 hydroxytryptamine*:ti,ab,kw OR rima*:ti,ab,kw OR 'monoamine oxidase
--

	inhibitor*.ti,ab,kw OR '5 ht*.ti,ab,kw #13 'antidepressant agent'/exp #14 #2 OR #12 OR #13 #15 #1 AND #5 AND #11 AND #14 #16 #15 AND 'human'/de
Database	The Cochrane Library
Search Terms	#1 MeSH descriptor: [Neoplasms] explode all trees #2 (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinoma* or adenocarcinoma* or choriocarcinoma* or lymphoma* or leukemia* or leukaemia* or metastat* or sarcoma* or teratoma* or epithelioma*) #3 #1 or #2 #4 MeSH descriptor: [Antidepressive Agents] explode all trees #5 MeSH descriptor: [Serotonin Uptake Inhibitors] explode all trees #6 MeSH descriptor: [Adrenergic Uptake Inhibitors] explode all trees #7 MeSH descriptor: [Monoamine Oxidase Inhibitors] explode all trees #8 MeSH descriptor: [Psychotropic Drugs] explode all trees #9 (psychotropic drug* or anti-depress* or antidepress* or tricyclic* or TCA* or serotonin uptake or SSRI* or SNRI* or monoamine oxidase inhibitor* or MAOI* or mao inhibitor* or thymoanaleptic* or thymoleptic* or 5 hydroxytryptamine* or 5 ht or rima*) #13 #4 or #5 or #6 or #7 or #8 or #9 or #11 #14 MeSH descriptor: [Morbidity] explode all trees #15 MeSH descriptor: [Incidence] explode all trees #16 MeSH descriptor: [Risk] explode all trees #17 (morbidity* or incidence* or occurrence* or genesis* or occur* or risk*)

	#18 #14 or #15 or #16 or #17 #19 MeSH descriptor: [Case-Control Studies] explode all trees #20 MeSH descriptor: [Cohort Studies] explode all trees #21 (cohort* or longitudinal* or prospective* or retrospective* or follow-up*) #22 case* #23 (control* or comparison* or compeer* or referent* or base*) #24 #22 and #23 #25 #24 or #19 or #20 or #21 #27 #25 and #18 and #13 and #3
Database	PsycINFO
Search Terms	#1 exp Neoplasms/ #2 (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinoma* or adenocarcinoma* or choriocarcinoma* or lymphoma* or leukemia* or leukaemia* or metastat* or sarcoma* or teratoma* or epithelioma*).mp. #3 1 or 2 #4 exp Monoamine Oxidase Inhibitors/ #5 exp serotonin reuptake inhibitors/ #6 exp antidepress/ #7 exp Psychotropic Drugs/ #8 (psychotropic drug* or anti-depress* or antidepress* or tricyclic* or TCA* or serotonin uptake or SSRI* or SNRI* or monoamine oxidase inhibitor* or MAOI* or mao inhibitor* or thymoanaleptic* or thymoleptic* or 5 hydroxytryptamine* or 5 ht or rima*).mp. #9 (anti-depress* or antidepress* or tricyclic* or TCA* or serotonin uptake or SSRI* or SNRI* or monoamine oxidase inhibitor* or MAOI* or mao inhibitor* or thymoanaleptic* or thymoleptic* or 5 hydroxytryptamine* or 5 ht or rima*).mp.

	#10 (desipramine* or imipramine* or clomipramine* or opipramol* or trimipramine* or lofepramine* or dibenzepin* or amitriptyline* or nortriptyline* or protriptyline* or doxepin* or iprindole* or melitracen* or butriptyline* or dosulepin* or amoxapine* or dimetacrine* or amineptine* or maprotiline* or quinupramine* or zimeldine* or fluoxetine* or citalopram* or paroxetine* or sertraline* or alaproclate* or fluvoxamine* or etoperidone* or escitalopram* or isocarboxazid* or nialamide* or phenelzine* or tranylcypromine* or iproniazide* or iproclozide* or moclobemide* or toloxatone* or oxitriptan* or tryptophan* or mianserin* or nomifensine* or trazodone* or nefazodone* or minaprine* or bifemelane* or viloxazine* or oxaflozane* or mirtazapine* or bupropion* or medifoxamine* or tianeptine* or pivagabine* or venlafaxine* or milnacipran* or reboxetine* or gepirone* or duloxetine* or agomelatine* or desvenlafaxine* or vilazodone* or hyperici herba* or hypericum perforatum* or st john* wort* or vortioxetine* or esketamine* or levomilnacipran* or Clovoxamine* or Clorgyline* or Dothiepin* or Sulpiride* or Rolipram*).mp. #11 (morbidity* or incidence* or occurrence* or genesis* or occur* or risk*).mp. #12 exp Morbidity/ #13 11 or 12 #14 exp Cohort analysis/ #15 exp Longitudinal Studies/ #16 exp Prospective Studies/ #17 (cohort* or longitudinal* or prospective* or retrospective* or follow-up*).mp. #18 case*.mp. #19 (control* or comparison* or compeer* or referrent* or base*).mp. #20 18 and 19 #21 14 or 15 or 16 or 17 or 20 #22 4 or 5 or 6 or 7 or 8 or 10 #23 3 and 13 and 21 and 22 #24 4 or 5 or 6 or 9 or 10 #25 3 and 13 and 21 and 24
--	--

[illegible]

Supplementary Material

Chan et al. (2015, cervical)	1	1	1	1	1	1	1	0	7
Wu et al. (2015, ovarian)	1	1	1	1	1	1	1	0	7
Ashbury et al. (2012, breast)	1	1	1	0	1	1	1	0	6
Walker et al. (2011, breast)	1	1	1	1	1	1	1	0	7
Wernli et al. (2009, breast)	1	1	1	0	2	0	1	0	6
Coogan et al. (2008, breast)	1	1	0	1	2	0	1	0	6
Davis et al. (2007,breast)	1	1	1	0	2	0	1	0	6
Chien et al. (2006,breast)	1	1	1	1	2	0	1	0	7

Fulton-Kehoe et al. (2006,breast)	1	1	1	0	2	1	1	0	7
Tamin et al. (2006, breast)	1	1	1	1	1	1	1	0	7
Coogan et al. (2005, breast)	1	1	0	1	1	0	1	0	5
Gonzalez-Perez et al. (2005, breast)	1	1	1	0	1	1	1	0	6
Moorman et al. (2005, ovarian)	1	1	1	1	1	0	1	0	6
Moorman et al. (2003, breast)	1	1	1	0	2	0	1	0	6
Steingart et al. (2003, breast)	1	1	1	1	2	0	1	0	7
Dublin et al. (2002, ovarian)	1	1	1	0	1	1	1	0	6

Supplementary Material									
Sharpe et al. (2002, breast)	1	1	1	0	0	1	1	0	5
Cotterchio et al. (2000, breast)	1	1	1	0	1	0	1	0	5
Coogan et al. (2000, ovarian)	1	1	0	1	1	0	1	0	5
Kelly et al. (1999, breast)	1	1	0	1	2	0	1	0	6
Harlow et al. (1998, ovarian)	1	1	1	0	2	0	1	0	6
Harlow et al. (1995, ovarian)	1	1	1	0	2	0	1	0	6
Cohort study (year, cancer types)	Selection				Comparability of cohorts on the basis of the design or analysis	Outcome			Total quality scores
	Representativeness of the	Selection of the	Ascertainment of	Demonstration that		Assessment	Was follow-up long enough	Adequacy of	

	exposed cohort	nonexpose d cohort	exposure	outcome of interest was not present at start of study		of outcome	for outcomes to occur?	follow- up of cohort	
Reeves et al.(2018, breast)	0	1	0	1	2	1	1	1	7
Brown et al. (2016, breast)	1	1	0	1	2	1	1	0	7
Chen et al. (2016, breast)	1	1	1	1	1	1	1	1	8
Sun et al. (2015, breast)	1	1	1	1	1	1	1	1	8
Haukka et al. (2010, breast, ovarian , Corpus uteri)	1	1	1	1	0	1	1	0	6
Wang et al. (2001, breast)	1	1	1	1	1	1	1	0	7

Kato et al.

(2000,
breast/ovarian/endo
metrial)

1	1	0	1	1	1	1	1	1	7
---	---	---	---	---	---	---	---	---	---


Supplementary Table 4. Reasons for Exclusion in Full-text Assessment

No.	Full text being excluded	Reasons
1	Dalton SO, Johansen C, Mellekjaer L, et al. Antidepressant medications and risk for cancer. <i>Epidemiology</i> . 2000;11(2):171-176. doi:10.1097/00001648-200003000-00015	shorting the data of incidence risk estimates of breast and gynecological cancer by antidepressant use
2	Shim EJ, Lee JW, Cho J, et al. Association of depression and anxiety disorder with the risk of mortality in breast cancer: A National Health Insurance Service study in Korea. <i>Breast Cancer Res Treat</i> . 2020;179(2):491-498. doi:10.1007/s10549-019-05479-3	shorting the data of incidence risk estimates of breast and gynecological cancer by antidepressant use
3	Lokugamage AU, Hotopf M, Hardy R, et al. Breast cancer in relation to childhood parental divorce and early adult psychiatric disorder in a British birth cohort. <i>Psychol Med</i> . 2006;36(9):1307-1312. doi:10.1017/S0033291706007914	shorting the data of incidence risk estimates of breast and gynecological cancer by antidepressant use
4	Liang X, Margolis KL, Hendryx M, et al. Effect of depression before breast cancer diagnosis on mortality among postmenopausal women. <i>Cancer</i> . 2017;123(16):3107-3115. doi:10.1002/cncr.30688	shorting the data of incidence risk estimates of breast and gynecological cancer by antidepressant use
5	Haque R, Enger SM, Chen W, Petitti DB. Breast cancer risk in a large cohort of female antidepressant medication users. <i>Cancer Lett</i> . 2005;221(1):61-65. doi:10.1016/j.canlet.2004.11.003	shorting the data of incidence risk estimates of breast and gynecological cancer by antidepressant use
6	Eskelinen M, Ollonen P. Forsen psychological risk inventory for breast cancer patients: a prospective case-control study with special reference to the use of psychiatric medications. <i>Anticancer Res</i> . 2011;31(2):739-744.	shorting the data of incidence risk estimates of breast and gynecological cancer by antidepressant use
7	Davis S, Mirick DK. Residential magnetic fields, medication use, and the risk of breast cancer. <i>Epidemiology</i> . 2007;18(2):266-269. doi:10.1097/01.ede.0000253934.58618.98	shorting the data of incidence risk estimates of breast and gynecological cancer by antidepressant use
8	Busby J, Mills K, Zhang SD, Liberante FG, Cardwell CR. Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study. <i>Breast Cancer Res</i> .	shorting the data of incidence risk estimates of breast and gynecological cancer by

	2018;20(1):4. Published 2018 Jan 19. doi:10.1186/s13058-017-0928-0	antidepressant use
9	Ballou Y, Rivas A, Belmont A, et al. 5-HT serotonin receptors modulate mitogenic signaling and impact tumor cell viability. <i>Mol Clin Oncol.</i> 2018;9(3):243-254. doi:10.3892/mco.2018.1681	shorting the data of incidence risk estimates of breast and gynecological cancer by antidepressant use
10	Azoulay L, Yin H, Renoux C, Suissa S. The use of atypical antipsychotics and the risk of breast cancer. <i>Breast Cancer Res Treat.</i> 2011;129(2):541-548. doi:10.1007/s10549-011-1506-2	shorting the data of incidence risk estimates of breast and gynecological cancer by antidepressant use
11	Anthony HM, Kenny TE, MacKinnon AU. Drugs in the aetiology of cancer: a retrospective study. <i>Int J Epidemiol.</i> 1982;11(4):336-344. doi:10.1093/ije/11.4.336	shorting the data of incidence risk estimates of breast and gynecological cancer by antidepressant use
12	Cohn E, Lurie I, Yang YX, et al. Posttraumatic Stress Disorder and Cancer Risk: A Nested Case-Control Study. <i>J Trauma Stress.</i> 2018;31(6):919-926. doi:10.1002/jts.22345	shorting the data of incidence risk estimates of breast and gynecological cancer by antidepressant use
13	Friedman GD, Udaltsova N, Chan J, Quesenberry CP Jr, Habel LA. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. <i>Cancer Causes Control.</i> 2009;20(10):1821-1835. doi:10.1007/s10552-009-9375-2	shorting the data of incidence risk estimates of breast and gynecological cancer by antidepressant use
14	Stebbing J, Powles T, Mandalia S, Nelson M, Gazzard B, Bower M. Use of antidepressants and risk of cancer in individuals infected with HIV. <i>J Clin Oncol.</i> 2008;26(14):2305-2310. doi:10.1200/JCO.2007.15.9681	1.1.1 shorting the data of incidence risk estimates of breast and gynecological cancer by antidepressant use for general population
15	Sun LM, Lin MC, Liang JA, et al. Does use of tetracyclic antidepressant-mirtazapine reduce cancer risk in depression patients?. <i>Pharmacoepidemiol Drug Saf.</i> 2013;22(12):1292-1297. doi:10.1002/pds.3523	shorting the data of incidence risk estimates of breast and gynecological cancer by antidepressant use
16	Sun LM, Lin MC, Liang JA, et al. Does use of tetracyclic antidepressant-mirtazapine reduce cancer risk in depression patients?. <i>Pharmacoepidemiol Drug Saf.</i> 2013;22(12):1292-	shorting the data of incidence risk estimates of breast and gynecological cancer by

	1297. doi:10.1002/pds.3523	antidepressant use
17	Huang T, Poole EM, Okereke OI, et al. Depression and risk of epithelial ovarian cancer: Results from two large prospective cohort studies. <i>Gynecol Oncol.</i> 2015;139(3):481-486. doi:10.1016/j.ygyno.2015.10.004	shorting the data of incidence risk estimates of breast and gynecological cancer by antidepressant use
18	Lacey JV Jr, Sherman ME, Hartge P, Schatzkin A, Schairer C. Medication use and risk of ovarian carcinoma: a prospective study. <i>Int J Cancer.</i> 2004;108(2):281-286. doi:10.1002/ijc.11538	shorting the data of incidence risk estimates of breast and gynecological cancer by antidepressant use
19	Ashbury JE, Lévesque LE, Beck PA, Aronson KJ. A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: the impact of duration of use, cumulative dose and latency. <i>BMC Med.</i> 2010;8:90. Published 2010 Dec 22. doi:10.1186/1741-7015-8-90	duplicate study data

Supplementary Figure 1. Dose-response for cumulative defined daily dose of antidepressant use and incidence risk of endometrial, corpus uteri and cervical cancer.



Abbreviations: AD: antidepressant; CDDD: cumulative defined daily dose.

The black solid line and the black long dashed line represent the estimated odds ratios (ORs) with corresponding 95% confidence intervals (CIs) for the non-linearity or the linearity.

Supplementary Figure 2. Leave-one-out sensitivity analyses for the risk of breast and gynecological cancer

